Table 2 Adherence of health practice guidelines (HPGs) to RIGHT checklist items addressing the domains of evidence and recommendations (total number and percentage with 95% confidence intervals (CI) of addressed items)
RIGHT checklist item | Croatian HPGs (n = 26) | European HPGs (n = 24) | Pa | BF10b |
|---|---|---|---|---|
Domain 3: Evidence | ||||
Healthcare questions | Total number (%, 95% CI) | |||
10a—State the key questions that were the basis for the recommendations in PICO (population, intervention, comparator, and outcome) or other format as appropriate. | 1 (3.8, 0.2–21.6) | 0 (0.0, 0.0–13.8) | 0.332 | 0.15 |
10b—Indicate how the outcomes were selected and sorted. | 1 (3.8, 0.2–21.6) | 0 (0.0, 0.0–13.8) | 0.332 | 0.14 |
Systematic reviews | ||||
11a—Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used. | 3 (11.5, 3.0–31.3) | 3 (12.5, 4.0–31.0) | 0.917 | 0.23 |
11b—If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed (provide the search strategies and the selection criteria, and describe how the risk of bias was evaluated) and whether they were updated. | 0 (0.0, 0.0–16.2) | 3 (12.5, 4.0–31.0) | 0.063 | 0.73 |
Assessment of the certainty of the body of evidence | ||||
12—Describe the approach used to assess the certainty of the body of evidence. | 19 (73.1, 51.9–87.7) | 18 (75.0, 55.1–88.0) | 0.877 | 0.30 |
Domain 4: Recommendations | ||||
Recommendations | ||||
13a—Provide clear, precise, and actionable recommendations. | 26 (100.0, 87.3–100.0) | 24 (100.0, 86.2–100.0) | 0.777 | NA |
13b—Present separate recommendations for important subgroups if the evidence suggests that there are important differences in factors influencing recommendations, particularly the balance of benefits and harms across subgroups. | 25 (96.2, 78.4–99.8) | 22 (91.7, 74.2–97.6) | 0.504 | 0.21 |
13c—Indicate the strength of recommendations and the certainty of the supporting evidence. | 21 (80.7, 60.2–92.7) | 21 (87.5, 69.0–95.7) | 0.517 | 0.31 |
Rationale/explanation for recommendations | ||||
14a—Describe whether values and preferences of the target population(s) were considered in the formulation of each recommendation. If yes, describe the approaches and methods used to elicit or identify these values and preferences. If values and preferences were not considered, provide an explanation. | 2 (7.7, 1.3–26.6) | 12 (50.0, 31.4–68.6) | < 0.001 | 80.63 |
14b—Describe whether cost and resource implications were considered in the formulation of recommendations. If yes, describe the specific approaches and methods used (such as cost effectiveness analysis) and summarize the results. If resource issues were not considered, provide an explanation. | 0 (0.0, 0.0–16.2) | 8 (33.3, 17.9–53.3) | < 0.001 | 55.15 |
14c—Describe other factors taken into consideration when formulating the recommendations, such as equity, feasibility and acceptability. | 2 (7.7, 1.3–26.6) | 6 (25.0, 12.0–44.9) | 0.095 | 0.93 |
Evidence to decision processes | ||||
15—Describe the processes and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such as how consensus was defined and achieved and whether voting was used). | 9 (34.6, 17.9–55.6) | 4 (16.7, 6.7–35.9) | 0.148 | 0.81 |